Press Releases

June 16, 2026
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
May 1, 2026
Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
March 23, 2026
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
March 18, 2026
Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren’s Syndrome
March 12, 2026
Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next Generation Premier Hb9210 HbA1c Column System
March 11, 2026
Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
March 10, 2026
Trinity Biotech Provides Business and Trading Update
March 10, 2026
Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
February 25, 2026
Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives
February 20, 2026
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
February 18, 2026
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement
February 10, 2026
Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation
February 10, 2026
Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026
December 23, 2025
Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives
December 23, 2025
Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests
December 15, 2025
Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution
November 18, 2025
Trinity Biotech Secures Regulatory Approval for Offshored and Outsourced Manufacturing of Uni-Gold Rapid HIV Test
November 14, 2025
Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test
September 2, 2025
Trinity Biotech Regains NASDAQ Compliance
August 22, 2025
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
August 21, 2025
Paul Tivnan appointed Non-Executive Director
August 20, 2025
TrinScreen – Local Reg Approval Final
August 14, 2025
NYSDOH New Preeclampsia Testing Approval
August 12, 2025
Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor
August 7, 2025
Trinity Biotech Announces Launch of FDA-cleared New Preeclampsia Testing Service
July 24, 2025
Trinity Biotech Unveils CGM+ An AI-Native Platform Targeting the $260 Billion AI Wearable Market
June 24, 2025
Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation
May 15, 2025
Trinity Biotech Publishes Fourth Quarter 2024 Results
March 13, 2025
Trinity Biotech Further Strengthens Focus
January 28, 2025
Trinity Biotech Announces Breakthrough on CGM
December 24, 2024
Trinity Biotech Announces Amended Credit Agreement
November 15, 2024
Trinity Biotech Announces Q3 2024 Financial Results
November 7, 2024
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
October 25, 2024
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
October 25, 2024
Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform
September 25, 2024
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market
September 18, 2024
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer
September 9, 2024
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
September 3, 2024
Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer
August 26, 2024
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales
August 20, 2024
Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director
August 14, 2024
Trinity Biotech Announces Q2 2024 Financial Results
August 6, 2024
Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements
August 2, 2024
Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience
July 9, 2024
Trinity Biotech Announces Appointment of A New CFO
June 10, 2024
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
May 23, 2024
Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
May 16, 2024
Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI
May 8, 2024
Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development
April 4, 2024
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
February 15, 2024
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
February 13, 2024
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
February 8, 2024
Trinity Biotech to Present at Emerging Growth Conference
February 7, 2024
Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code
January 31, 2024
Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.
January 31, 2024
Trinity Biotech Announces Q3 2023 Financial Results & Business Update
January 31, 2024
Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India